Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.
Natural killer (NK) cells are at the crossroad between innate and adaptive immunity and play a major role in cancer immunosurveillance. NK cell stimulation depends on a balance between inhibitory and activating receptors, such as the stimulatory lectin-like receptor NKG2D. To redirect NK cells against tumor cells, we designed bifunctional proteins able to specifically bind tumor cells and to induce their lysis by NK cells, after NKG2D engagement. To this aim, we used the 'knob into hole' heterodimerization strategy, in which 'knob' and 'hole' variants were generated by directed mutagenesis within the CH3 domain of human IgG1 Fc fragments fused to an anti-CEA or anti-HER2 scFv or to the H60 murine ligand of NKG2D, respectively. We demonstrated the capacity of the bifunctional proteins produced to specifically coat tumor cells surface with H60 ligand. Most importantly, we demonstrated that these bifunctional proteins were able to induce an NKG2D-dependent and antibody-specific tumor cell lysis by murine NK cells. Overall, the results show the possibility to redirect NK cytotoxicity to tumor cells by a new format of recombinant bispecific antibody, opening the way of potential NK cell-based cancer immunotherapies by specific activation of the NKG2D receptor at the tumor site.
Germain
Claire
C
IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier1, Montpellier F-34298, France.
Campigna
Emmanuelle
E
Salhi
Imed
I
Morisseau
Sébastien
S
Navarro-Teulon
Isabelle
I
Mach
Jean-Pierre
JP
Pèlegrin
André
A
Robert
Bruno
B
D000818:Animals; D015153:Blotting, Western; D016923:Cell Death / Q000276:immunology; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D015180:Electrophoresis, Gel, Two-Dimensional; D058851:GPI-Linked Proteins; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D015778:Minor Histocompatibility Antigens / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000378:metabolism
D058851:GPI-Linked Proteins; D036341:Intercellular Signaling Peptides and Proteins; D015778:Minor Histocompatibility Antigens; D011994:Recombinant Proteins; C423230:ULBP2 protein, human; C114735:minor H antigen H60
Int J Cancer. 1989 Oct 15;44(4):738-43
2793246
Blood. 2005 Sep 1;106(5):1711-7
15886320
Cancer Res. 2003 Dec 15;63(24):8996-9006
14695218
Immunity. 2002 Jul;17(1):19-29
12150888
Nat Rev Microbiol. 2005 Jan;3(1):59-69
15608700
J Immunol. 2002 Oct 15;169(8):4098-102
12370336
Immunol Today. 1997 Feb;18(2):89-95
9057360
Hybridoma. 1991 Jun;10(3):347-56
1916847
Nat Rev Cancer. 2001 Nov;1(2):118-29
11905803
J Immunother. 1999 Nov;22(6):514-24
10570750
Nat Biotechnol. 2003 Dec;21(12):1486-92
14634668
Clin Cancer Res. 2005 Oct 15;11(20):7516-22
16243826
J Invest Dermatol. 2002 Apr;118(4):600-5
11918705
Nature. 2001 Sep 13;413(6852):165-71
11557981
Hum Immunol. 2006 Mar;67(3):183-7
16698440
Blood. 2000 Mar 15;95(6):2098-103
10706880
Nat Rev Immunol. 2006 Jul;6(7):520-31
16799471
Immunity. 2001 Aug;15(2):201-11
11520456
Immunity. 2001 Feb;14(2):123-33
11239445
Br J Cancer. 2000 Mar;82(5):1058-62
10737389
Nature. 1983 Oct 6-12;305(5934):537-40
6137772
Biochem Soc Trans. 2002 Aug;30(4):507-11
12196124
J Biol Chem. 2007 Apr 27;282(17):12650-60
17347147
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2731-6
10694580
Nat Immunol. 2000 Aug;1(2):119-26
11248803
Blood. 1999 Oct 15;94(8):2562-8
10515858
Acta Pharmacol Sin. 2005 Jan;26(1):1-9
15659107
Int J Cancer. 1992 Aug 19;52(1):110-9
1500216
Hum Gene Ther. 2006 Feb;17(2):135-46
16454647
Cancer Res. 1996 Oct 15;56(20):4758-65
8840995
Biochem Biophys Res Commun. 2003 May 23;305(1):129-35
12732206
Int J Cancer. 1999 Apr 12;81(2):285-91
10188732
J Exp Med. 1984 Dec 1;160(6):1686-701
6239899
Blood. 2005 Jan 1;105(1):251-8
15328155
Science. 1999 Jul 30;285(5428):727-9
10426993
Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6259-63
8022771
Cancer Res. 2002 Nov 1;62(21):6178-86
12414645
Nat Rev Cancer. 2002 Nov;2(11):850-61
12415255
Nat Immunol. 2005 Sep;6(9):928-37
16116470
Nat Biotechnol. 1998 Jul;16(7):677-81
9661204
Blood. 2006 Mar 1;107(5):1955-62
16210338
Immunity. 2000 Jun;12(6):721-7
10894171
Methods Enzymol. 2000;322:325-45
10914028
J Immunol Methods. 2005 Jan;296(1-2):95-101
15680154
Cancer Immun. 2001 Mar 30;1:2
12747763
J Immunol. 2002 Oct 15;169(8):4079-83
12370332
Protein Eng. 1996 Jul;9(7):617-21
8844834
Mol Immunol. 1991 Sep;28(9):1027-37
1922108
J Exp Med. 1985 Jan 1;161(1):40-52
2981954
Cancer Res. 1998 Apr 1;58(7):1469-77
9537250
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11521-6
11562472
Blood. 2003 Aug 15;102(4):1389-96
12714493
Annu Rev Immunol. 2001;19:197-223
11244035
Curr Top Microbiol Immunol. 1998;230:193-220
9586357
J Immunol. 1998 Oct 1;161(7):3501-9
9759870
J Clin Invest. 2008 Mar;118(3):994-1005
18259610
Nat Immunol. 2001 Mar;2(3):255-60
11224526
Br J Cancer. 2004 Oct 18;91(8):1495-9
15381927